Revolution Medicines, Inc.
RVMD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.32 | -0.44 | 350,978,128,094,549.75 | -0.47 |
| FCF Yield | -2.38% | -3.31% | -2.97% | -1.90% |
| EV / EBITDA | -27.84 | -25.50 | -27.23 | -32.55 |
| Quality | ||||
| ROIC | -15.59% | -11.66% | -10.85% | -8.95% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.68 | 0.89 | 0.91 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 8.09% | -15.94% | -41.71% | -4.16% |
| Safety | ||||
| Net Debt / EBITDA | 0.19 | 1.03 | 0.84 | 1.91 |
| Interest Coverage | -27.59 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,552.88 | -1,343.63 | -20.78 | -26.04 |